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http://dx.doi.org/10The mevalonate pathway provides metabolites for post-translational modifications such as
farnesylation, which are critical for the activity of RAS downstream signaling. Subsequently
occurring regulatory processes can induce an aberrant stimulation of DNA methyltransferase
(DNMT1) as well as changes in histone deacetylases (HDACs) and microRNAs in many can-
cer cell lines. Inhibitors of the mevalonate pathway are increasingly recognized as anticancer
drugs. Extensive evidence indicates an intense cross-talk between signaling pathways, which
affect growth, differentiation, and apoptosis either directly or indirectly via epigenetic mecha-
nisms. Herein, we show data obtained by novel transcriptomic and corresponding methylomic
or proteomic analyses from cell lines treated with pharmacologic doses of respective inhibitors
(i.e., simvastatin, ibandronate). Metabolic pathways and their epigenetic consequences appear
to be affected by a changed concentration of NADPH. Moreover, since the mevalonate meta-
bolism is part of a signaling network, including vitamin D metabolism or fatty acid synthesis,
the epigenetic activity of associated pathways is also presented. This emphasizes the
far-reaching epigenetic impact of metabolic therapies on cancer cells and provides some
explanation for clinical observations, which indicate the anticancer activity of statins and
bisphosphonates.
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license (http://creativecommons.org/licenses/by/4.0/).For more than 100 years, it has been known that cholesterol
may accumulate in cancerous tissues (1) and plays a critical
role in cancer progression, thus emphasizing the therapeutic
potential of lowering cholesterol and downregulating the
mevalonate pathway in cancer prevention and treatment (2).
The mevalonate pathway converts acetyl-coenzyme A
(acetyl-CoA) to isoprenoids, thus supplying key metabolites
for cholesterol and steroid synthesis. It comprises a series ofmber 28, 2014; received in revised form February
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.1016/j.cancergen.2015.03.008enzymatic reactions that occur in the endoplasmic reticulum.
The rate-limiting step is catalyzed by 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, which
converts HMG-CoA to mevalonate. This reaction is inhibited
by statins, whereas bisphosphonates target more
downstream reactions in this pathway, such as farnesylation
and geranylgeranylation.
Meanwhile, there exists an increasing amount of data,
which indicate that statins, as well as bisphosphonates,
target the three most important epigenetic levels: DNA
methylation, histone deacetylation, and microRNAs
(Figure 1).
The best-described epigenetic roles of statins and
bisphosphonates result from a reduction of the membrane
anchoring from RAS and associated signaling toward DNAen access article under the CC BY license (http://creativecommons.
Figure 1 Inhibition of the mevalonate pathway influences the stability of the plasma membrane. It inhibits isoprenylation of the small
GTP-binding proteins and, therefore, the activity of RAS signaling. As a consequence, RAS signals via RAF into the MAPK pathway,
an inhibited signaling via FLI1 and JNK (c-JUN N-terminal kinase), leads to a downregulation of DNMT1. The cross-talk of RAS with
PI3K-AKT-mTOR signaling influences the expression of HDACs. Additional metabolic pathways influenced by RAS signaling are
glucose uptake and the OCM, which may both be fueled by activating mutations of the P53 gene (TP53) and play essential roles in
DNA repair and inflammation. Similar to the inhibition of HMG-Co-A reductase, a downregulation of these pathways changes the
concentration of NADPH. In addition, there is also a downregulation of the RHOA-ROCK signaling and the associated vitamin D
degrading enzyme CYP24A1 (18). This could induce a series of vitamin Dassociated effects on fatty acid metabolism and epige-
netics, for example (13).
242 H. Karlic et al.demethylation (3,4), or downregulation of the histone
deacetylase HDAC2 via the RAS/PI3K/mTOR pathway (5) in
addition to a direct competitive inhibition of HDAC2 by statins
(6). Reduction of homocysteine, which is produced in the one
carbon metabolism (OCM), also leads to a downregulation of
the DNA methyltransferase DNMT1 (7) and a shift in the
NAD(P)þ/NAD(P)H-ratio toward NADP, with apparent con-
sequences for histone modifications (8e10) and DNA repair
through breakdown of poly-ADP-ribose (9). The down-
regulation of geranylgeranylation of another small GTPase,
RHOA, and associated signaling (11) downregulates HDAC1
(12) and promotes vitamin Dassociated epigenetic effects
(13e15) by preventing CYP24A1-induced degradation of
vitamin D3 (16e18).
In this study, simvastatin was chosen as a representative
statin for transcriptomic studies, because a large-scale inves-
tigation was already performedwith this drug and it was the first
statin drug used extensively in clinical practice for control of
elevated cholesterol. Epigenetic studies with simvastatin
emphasize its roleasadirect inhibitorofHDAC1andHDAC2 (6)
orasan inducerof respectivemicroRNAs(19e21). Ibandronate
was selected as a representative bisphosphonate, because it is
already known for its epigenetic impact (3).Materials and methods
Cell cultivation treatment and NADPD/NADPH
analyses
Cells were cultivated in cell culture flasks at 37Cand 5%CO2.
The culture media were as recommended by the American
Type Culture Collection (ATCC) for MDA-MB-231 breast
cancer DMEM (Sigma-Aldrich, St. Louis, MO, USA), which
contained 10% fetal calf serum (FCS); PC-3 prostate carci-
noma DMEM-F12 (Sigma-Aldrich) with 10% FCS. MG-63 and
U2-OS osteosarcoma were cultured in AlphaMEM (Biochrom,
Berlin, Germany) medium containing 10% FBS. For the
HMC1.1 cell line, we used Iscove’s Modified Dulbecco’s
Medium (IMDM; Thermo Fisher Scientific, Waltham,
MA) supplemented with 260 nM thioglycerol (Sigma-Aldrich)
and20% fetal bovine serum (FBS). All culturemedia contained
10 mg/mL gentamycin (Sigma-Aldrich). To guarantee optimal
growth, cells were split two times a week and reseeded at a
density of 25  105 cells/mL.
One day after splitting, 32mMsimvastatin (Sigma-Aldrich) or
150 mM ibandronate (Sigma-Aldrich) were added to the culture
Figure 2 NAD(P)þ biosynthesis and major NAD(P)þ-medi-
ated signaling pathways affect histone (de)acetylation (modified
according to (36)). Simvastatin and ibandronate induce upre-
gulation of the NMNAT (nicotineamide mononucleotide acetyl-
transferase), which synthesizes NAD from ATP and NMN
(nicotineamide mononucleotide). NADþ-consuming reactions
from PARP (polyADP ribose polymerase), HDACs, and sirtuins
are downregulated by inhibitors of mevalonate synthesis in
cancer cells.
Mevalonate pathway, epigenetics, and cancer 243medium for 72 hours. This is the dose that attenuated cell pro-
liferation with a half maximal effect (EC50) (data not shown).
NADP/NADPH analyses were performed directly in 96-
well culture plates after 24 or 48 hours, according to the
manufacturers’ instructions of the NADP/NADPH Glo Assay
(Promega, Madison, WI, USA).
Gene expression analysis
For comparative analysis of selected genes, we synthesized
cDNAwith theFirstStrandcDNASynthesisKit asdescribedby
the supplier (Roche, Rotkreuz, Risch, Switzerland). The ob-
tained cDNA was subjected to PCR amplification with a real-
time thermal cycler (Corbett Research; Fisher Scientific,
Schwerte, Germany). FAM-labeled TaqMan gene expression
probes and primers sets (all from Applied Biosystems, Foster
City, CA) were used according to the conditions suggested by
the suppliers. For normalization of expression, we used VIC-
labeled GAPDH and 18S TaqMan probes and primers sets in
the same reaction vial (GAPDH 4310884E, 18S 4319413E;
Applied Biosystems). Quantification of mRNA expression
within the samples was examined using the comparative Ct
method (22).
Transcriptomics and proteomics analysis
Analysis and data evaluation for the Affymetrix arrays (Type
Human Gene 1.0 ST Array; Affymetrix, Santa Clara, CA,
USA) were commercially obtained from an internationally
certified institution (Kompetenzzentrum f€ur Biofluoreszenz,
Regensburg, Germany). PathVisio software (23) was applied
for specific analyses of defined pathways from Affymetrix
arrays (Type Human Gene 1.0 ST Array). Proteomics ana-
lyses were conducted as described (24,25).
Results
Downregulation of DNA methyltransferase
Blocking the mevalonate pathway inhibits isoprenylation of
the small GTP-binding proteins and, therefore, the activity of
signaling from GTP-binding proteins such as RAS. RAS
signals via RAF into the MAPK pathway (26,27).
Consequently, the whole cascade is affected and associated
DNMT1 expression (4,28) is downregulated (Figures 1 and 2,
Table 1) (4).
Such data could explain far-reaching consequences,
including demethylation and activation of key mediators ofTable 1 Effect of ibandronate and simvastatin on the key epigene
Gene expression U2-Ibn MG-Ibn PC-Ibn MDA-
DNMT1 basal expression 10.0 11.3 10.8 11.3
DNMT1 treated expression 9.7 11.3 10.0 11.3
DNMT1 fold expression L1.21* 1.02† L1.73* 1.00
Abbreviations: U2, U-2 OS; Ibn, ibandronate; MG, MG-63 osteosarcom
cancer cells; Sim, simvastatin; A2780, A2780 ovarian cancer cell line; C
a All data were derived from Affymetrix ST1.0 expression microarrays,
treatment with the following drugs: 150 mM ibandronate, 32 mM simvastati
genes in the microarrays; * Z fold downregulation and † Z fold upregulapoptosis (3) and differentiation (29), and would have a major
impact onmetabolism (30). In addition, upregulation of DNMTs
in malignancies may be driven by HDAC2 (31). Thus, a
drug-induced downregulation of these enzymes underscores
the anticancer activity of statins and bisphosphonates.
Downregulation of HDACs
Our transcriptomic analyses indicated a downregulation of
histone deacetylases (Table 2).
The expression of HDACs is influenced not only by the
cross-talk of RAS with PI3K-AKT-mTOR signaling (32)
(Figure 1 and Table 2) (4), but also by metabolites such as
NAD(P)þ and NAD(P)H, which are also targeted by
metabolic modifiers such as statins. Besides the “classical”
NAD-dependent histone deacetylases from the SIRT family,
HDAC1 and HDAC2 are also regulated by this metabolite
(33), as shown in Figure 1 (4) and Table 2.
Regulation of microRNAs
The mean percentage of significantly downregulated
microRNAs in a total of 1,199 microRNAs, which were
detectable in our gene chips, was 14.8% in simvastatin-tic regulator DNMT1a
Ibn U2-Sim MG-Sim PC-Sim MDA-Sim A2780-C75
10.0 11.3 11.6 11.3 9.6
9.5 11.3 10.3 10.0 8.8
L1.47* 1.06† L2.47* L2.56* L1.75*
a cells; PC, PC-3 prostate cancer cells; MDA, MDA-MB-231 breast
75, inhibitor of fatty acid synthase.
which were used for analysis of mRNA from cell lines after 3 days of
n, 27 mM C75). Expression levels are in relation to the set of standard
ation.
Table 2 Down-regulation of HDACs by inhibitors of the mevalonic acid pathwaya
Gene expression U2-Ibn MG-Ibn PC-Ibn MDA-Ibn U2-Sim MG-Sim PC-Sim MDA-Sim HMC-Sim
HDAC1 basal expression 10.9 10.2 12.2 10.0 10.5 10.2 11.0 10.0 10.2
HDAC1 treated expression 10.8 9.9 11.9 9.9 10.7 10.1 10.1 9.7 9.4
HDAC1 fold expression L1.10* L1.28* L1.21* L1.14* 1.11† L1.07* L1.85* L1.31* L1.69*
HDAC2 basal expression 10.5 4.6 10.6 8.4 10.5 4.6 8.4 4.3 7.9
HDAC2 treated expression 10.0 4.5 10.0 8.3 10.4 4.6 8.0 4.5 7.0
HDAC2 fold expression L1.38* L1.07* L1.44* L1.14* L1.06* 1.04† L1.30* 1.19† L1.84*
HDAC3 basal expression 10.7 9.8 10.9 9.9 10.4 9.8 10.0 9.9 9.8
HDAC3 treated expression 10.2 9.4 10.6 10.1 10.6 9.6 9.6 9.9 9.3
HDAC3 fold expression L1.40* L1.33* L1.26* 1.09† 1.13† L1.20* L1.30* L1.00 L1.26*
HDAC7 basal expression 9.1 9.3 8.8 9.1 9.1 9.3 9.3 9.1 9.1
HDAC7 treated expression 8.8 9.2 8.6 9.2 9.0 9.5 8.9 9.0 9.0
HDAC7 fold expression L1.28* L1.13* L1.14* 1.03† L1.09* 1.08† L1.34* L1.08* L1.08*
HDAC8 basal expression 9.7 8.1 9.8 8.0 9.7 8.1 8.1 8.0 8.7
HDAC8 treated expression 9.1 7.4 9.6 8.1 9.7 7.8 8.1 7.7 8.7
HDAC8 fold expression L1.49* L1.68* L1.14* 1.03† L1.02 L1.25* L1.01 L1.28* L1.05*
Abbreviations: HMC, HMC1.1 mast cell line; U2, U-2 OS; MG, MG-63 osteosarcoma cells; MDA, MDA-MB-231 breast cancer cells; PC, PC-3
prostate cancer cells; HMC, HMC1.1 mast cell line; Ibn, ibandronate; Sim, simvastatin; C75, inhibitor of fatty acid synthase.
a All data are derived from Affymetrix ST1.0 expression microarrays, which were used for analysis of mRNA from cell lines after 3 days
treatment with respective drugs (150mM ibandronate, 32mM simvastatin, 27mM C75). Expression levels are in relation to the set of standard
genes in the microarrays; * Z fold downregulation and † Z fold upregulation.
244 H. Karlic et al.treated and 14.2% in ibandronate-treated cell lines.
MicroRNA-34a, which regulates the NADþ-dependent his-
tone deacetylase SIRT1 as well, as HDAC1 and HDAC7
(2,34), was downregulated with simvastatin in all cancer cell
lines investigated in this study, but most significantly in
simvastatin-treated MDA-MD-231 cells (Table 3).
The mean percentage of significantly upregulated micro-
RNAs in a total of 1,199 microRNAs, which were detectable
in our gene chips, was 21.9% in simvastatin-treated and 14.4
% in ibandronate-treated cell lines. The most significantly
upregulated microRNA in simvastatin-treated MDA-MB 231
cells was microRNA-612, which is known to reduce stem-
ness and to attenuate resistance against 5-fluorouracil in
cancer cells (35). MicroRNA-612 was also significantly
upregulated in simvastatin-treated PC-3 cells as well as in
MG-63 and HMC-cells, which had been treated with simva-
statin (Table 3).Epigenetic impact of OCM
Data from our genome-wide expression analysis indicated
that the majority of transcribed genes from folateTable 3 Down-regulation of microRNA MIR-34A and up-regulation
Gene expression MG-Sim
MIR-34A basal expression 6.3
MIR-34A treated expression 6.1
MIR-34A fold expression L1.10*
MIR-612 basal expression 7.1
MIR-612 treated expression 7.9
MIR-612 fold expression 1.65†
Abbreviations: U2, U-2 OS; MG, MG-63 osteosarcoma cells; MDA, MDA
HMC1.1 mast cell line; Ibn, ibandronate; Sim, simvastatin; C75, inhibitor
a All data are derived from Affymetrix ST1.0 expression microarrays,
treatment with respective drugs (150mM ibandronate, 32mM simvastatin,
genes in the microarrays; * Z fold downregulation and † Z fold upregulmetabolism, which is also known as OCM, was down-
regulated by simvastatin in HMC 1.1, U2-OS, and MDA-231
cells at the mRNA level (Figure 3). Proteomic data from U2-
OS also confirmed this at the protein level.
The “starter” molecule of OCM dihydrofolate reductase
(DHFR) is the target for many anticancer and antibiotic thera-
pies, including methotrexate and trimethoprim. In our study,
DHFRwasdownregulated in theU2-OSproteomic assay:8%
by ibandronateand49%bysimvastatin.OCMisalsoknown to
provide keymetabolites, such asNAD(P)þ, which are important
cofactors for histone-modifying enzymes (33,36,37).
Downregulation of the enzymes that are important for
synthesis of polyglutamate suggests a lowering of the pool of
metabolites that are important for folate synthesis, in addition
to an increased NADPþ/NADPH ratio in responsive cell lines,
such as MDA-MB-231, but not in less aggressive cells such
as MG-63. This could provide an explanation for previous
observations indicating that a combined treatment of Ehrlich
carcinoma cells with the cholesterol-lowering drug atorvas-
tatin showed an additive effect with methotrexate on tumor
tissue volume and of the apoptotic index (38). An explanation
for this finding was the downregulation of most enzymes of
the OCM by simvastatin, as shown in Figure 3, in three tumorof microRNA MIR-612 by simvastatina
PC-Sim MDA-Sim HMC-Sim
7.7 6.3 6.4
7.5 6.0 6.4
L1.16* L1.24* L1.01
5.9 8.1 7.9
6.6 9.0 9.4
1.65† 1.82† 2.88†
-MB-231 breast cancer cells; PC, PC-3 prostate cancer cells; HMC,
of fatty acid synthase.
which were used for analysis of mRNA from cell lines after 3 days
27mM C75). Expression levels are in relation to the set of standard
ation.
Figure 3 Results from a transcriptomic analysis of the OCM: Downregulated genes were, dependening on their level colored in green,
upregulated in red. The analyzed cell lines are from the left to the right: U2OS osteosarcoma treated with ibandronate and simvastatin; PC-3
prostate cancer cells treated with ibandronate. The labels are the actual gene names according to the NCBI gene database. Abbreviations:
MTHFD, methylenetetrahydrofolate dehydrogenase;MTHFR, methylenetetrahydrofolate reductase;DHFR, dihydrofolate reductase;TYMS,
thymidylatesynthetase;SHMT,serinehydroxymethyltransferase;AHCYL1,adenosylhomocysteinase-like1;MTR, 5-methyltetrahydrofolate-
homocysteine methyltransferase; DNMT1, DNA (cytosine-5-)-methyltransferase 1;MAT2B, methionine adenosyltransferase II, beta.
Mevalonate pathway, epigenetics, and cancer 245cell lines that may act additionally to the inhibition of the
DHFR by methotrexate (Table 4), however, it is not clear
which of these pathways is responsible for the anti-
proliferative effect of statins.
However, this could also be due to a lack of NADPH,
because the following NADPH-producing reactions are
downregulated by statins: 1) glycolysis, including the
NADPH-producing pentose-phosphate cycle as well as the
KREBS or tricarbonic acid cycle (39), 2) the fatty acid
oxidation (40), 3) the OCM, which was identified as a major
producer of NADPH by quantitative flux analysis (41), and
4) TYMS, which is among the most downregulated genes
analyzed in our transcriptomic study, is known to convert
dUMP to dTMP in the presence of NADPH and serine (42).
Thus, a lack of NADPH could be responsible for the
downregulation of this gene in responsive cell lines
(Table 4).Table 4 Effect of ibandronate and simvastatin on key enzymes of
Gene expression U2-Ibn MG-Ibn PC-Ibn MDA-I
DHFR basal expression 10.3 7.9 10.4 7.5
DHFR treated expression 10.0 7.7 9.2 7.3
DHFR fold expression L1.16* L1.11* L2.25* L1.14
TYMS basal expression 11.9 11.1 11.5 10.7
TYMS treated expression 11.9 10.9 9.8 10.4
TYMS fold expression L1.05* L1.21* L3.18* L1.23
Abbreviations: U2, U-2 OS; MG, MG-63 osteosarcoma cells; MDA, MDA-
A2780 ovarian cancer cell line; Ibn, ibandronate; Sim, simvastatin; C75,
a All data are derived from Affymetrix ST1.0 expression microarrays,
treatment with respective drugs (150mM ibandronate, 32mM simvastatin,
genes in the microarrays; * Z fold downregulation and † Z fold upregulThe link to epigenetics is emphasized by data indicating
that NADPH can stimulate class I HDAC activity in vitro and
in vivo (33). This affects regulation of the protein poly (ADP-
ribose) polymerase (PARP) and associated effects on chro-
matin relaxation and DNA repair (43). Thus, a lack of NADPH
could explain the observed downregulation of HDACs and
the observed downregulation of DNA repair factors by sim-
vastatin (Figure 2).
Inhibitors of the HMGCR (44,45) and DHFR enzymes are
known for their anti-inflammatory activities (46), which are
related to their antioxidant properties resulting from inhibition
of NADPH-dehydrogenases. By our proteomic analysis of
simvastatin-treated U2OS NADH-dehydrogenases, NDUFA8
(4%), NDUFV2 (8%), and NDUFS2 (20%) were down-
regulated, in addition to the NADH cytochrome B5 reductase
CYB5R1 (34%) and the NADþ-dependent HDAC, SIRT1
(3.2%).OCM, namely DHFR and TYMSa
bn U2-Sim MG-Sim PC-Sim MDA-Sim A2780-C75
10.2 7.9 7.6 7.5 9.9
10.0 7.7 8.0 6.5 9.4
* L1.10* L1.17* 1.32† L2.03* L1.37*
11.9 11.1 11.2 10.7 10.7
11.8 11.1 8.2 7.1 9.6
* L1.07* 1.00 L7.82* L12.40* L2.12*
MB-231 breast cancer cells; PC, PC-3 prostate cancer cells; A2780,
inhibitor of fatty acid synthase.
which were used for analysis of mRNA from cell lines after 3 days
27mM C75). Expression levels are in relation to the set of standard
ation.
Table 5 Expression of LOX was stimulated both by simvastatin and ibandronatea
Gene expression U2-Ibn MG-Ibn PC-Ibn MDA-Ibn U2-Sim MG-Sim PC-Sim MDA-Sim
LOX basal expression 9.3 9.3 8.3 10.2 8.9 9.3 7.9 10.2
LOX treated expression 10.0 10.0 9.8 10.3 9.5 9.6 9.9 10.6
LOX fold expression 1.60† 1.67† 2.90† 1.09† 1.50† 1.22† 4.19† 1.39†
Abbreviations: U2, U-2 OS; MG, MG-63 osteosarcoma cells; MDA, MDA-MB-231 breast cancer cells; PC, PC-3 prostate cancer cells; Ibn,
ibandronate; Sim, simvastatin; C75, inhibitor of fatty acid synthase.
a All data are derived from Affymetrix ST1.0 expression microarrays, which were used for analysis of mRNA from cell lines after 3 days
treatment with respective drugs (150mM ibandronate, 32mM simvastatin, 27mM C75). Expression levels are in relation to the set of standard
genes in the microarrays; * Z fold downregulation and † Z fold upregulation.
246 H. Karlic et al.Inhibition of the OCM downregulates the production of
homocysteine (Hcys) (see Figure 3) (47). Hcys promotes the
production of serum amyloid A (SAA) (48), and this is associ-
ated with a stimulation of inflammatory interleukins (49).
Hcys modulates expression of osteoblastic genes, but
most important, it downregulates procollagen-lysine-1,2-
oxoglutarate-5-dioxygenases as well as lysyl oxidase (LOX ).
The downregulation of both genes, which are involved in
collagen cross-linking could contribute to decreased bone
matrix quality. We have shown that the downregulation of LOX
is mediated by Hcys via interleukin-6 (IL6), Friend leukemia
integration 1 (FLI1), and DNMT1 and epigenetically regulated
via promoter methylation (7). This has a relevance to
inflammation-associated osteopenia, which is associated with
a downregulation of LOX in response to tumor necrosis factor
alpha (TNFa) (50). Pathologically inhibited LOX is upregulated
by statins via inhibition of geranylgeranylated proteins, such
as Rho-kinases (51), as well as by promoter demethylation
(based on our own data). Table 5 demonstrates that the
bisphosphonate ibandronate upregulated LOX as well. Recent
findings suggest a similar mechanism for LOX (7) by
demonstrating that the bisphosphonates upregulate FAS via
promoter demethylation.
Regulation of vitamin D metabolism by inhibitors
of mevalonic acid metabolism may also affect
epigenetic mediators
As shown in Figure 1, inhibitors of the mevalonic acid
pathway have the potential to upregulate vitamin D meta-
bolism through attenuation of a vitamin D degrading enzyme.
In addition, inhibitors of fatty acid synthase (FASN), such
as C75, may also target the mevalonic acid pathway (52)
and RAS activity. In our study, FASN was downregulated
by inhibitors of the mevalonic acid pathway, which
confirmed previous studies (53). As shown in Table 6,Table 6 Expression of FASN was regulated both by simvastatin a
Gene expression U2-Ibn MG-Ibn PC-Ibn
FASN basal expression 10.5 10.9 10.3
FASN treated expression 9.8 10.9 10.1
FASN fold expression L1.63* L1.03 L1.17*
Abbreviations: U2, U-2 OS; MG, MG-63 osteosarcoma cells; MDA, MD
ibandronate; Sim, simvastatin; C75, inhibitor of fatty acid synthase.
a All data are derived from Affymetrix ST1.0 expression microarrays,
treatment with respective drugs (150mM ibandronate, 32mM simvastatin,
genes in the microarrays; * Z fold downregulation and † Z fold upregulFASN was downregulated by inhibitors of the mevalonic
acid pathway.
Furthermore, the association between FASN down-
regulation and PI3K signaling, which is already documented
(54e57), could be confirmed by our data from respective
genome-wide expression analyses (Figure 4), which included
the FASN inhibitor C75 as a control, thus emphasizing this
pathway as a potential target for anticancer therapy (58).
FASN inhibitors cerulenin and C75 induce cell cycle arrest
and apoptosis in tumor cells. This is associated with eleva-
tion of CDKN1A (P21) (59), and similar effects were also
observed upon treatment with statins (6) or 1,25-dihydroxy
vitamin D3 (VD) (60). Interestingly, some authors
mentioned that statins might induce an increase of VD (61),
which appears to be a paradox, because VD synthesis de-
pends on metabolites from the mevalonic acid pathway.
However, it appears possible that statin-induced upregula-
tion of the ATP-binding cassette transporter (62), which is
also responsible for VD uptake, (63) could explain this phe-
nomenon, in addition to the statin-induced downregulation of
the vitamin D degrading enzyme CYP24A1 (17). Although
speculative, it could also be possible that an additional
pathway for isoprenoid synthesis, which is characteristic for
bacteria (64), might have been “imported” by endosymbionts
via phagocytosis.
A further comparative evaluation of our genome-wide
expression analyses shows that drugs that downregulate
FASN also downregulate OCM and vice versa (Figure 4).Discussion
Downregulation of DNA methyltransferase
Our data (Table 1) confirm that statins exhibit demethylating
properties. Inhibition of DNMTs can be seen even at lownd ibandronatea
MDA-Ibn U2-Sim MG-Sim PC-Sim MDA-Sim
9.6 10.3 10.9 10.4 9.6
9.6 10.2 11.1 8.8 9.5
1.02† L1.09* 1.16† L3.03* L1.04
A-MB-231 breast cancer cells; PC, PC-3 prostate cancer cells; Ibn,
which were used for analysis of mRNA from cell lines after 3 days
27mM C75). Expression levels are in relation to the set of standard
ation.
Figure 4 Effect of a FASN inhibitor (C75) or vitamin D3 on epigenetic regulators (DNMT1 and HDAC2, key enzymes of OCM DHFR
and TYMS, as well as FASN.
Mevalonate pathway, epigenetics, and cancer 247statin concentrations (0.25 mM), which are comparable to the
serum levels of approximately 0.1 mM measured in patients
treated with standard doses for hypercholesterolemia and far
lower than the maximum safely achievable levels in humans.
These low concentrations of statins are safe and well toler-
ated by patients for years. Thus, in contrast with many known
DNMT inhibitors, statins downregulate DNMTs and induce
DNA demethylation at nontoxic doses (29).
Downregulation of HDACs
Our transcriptomic studies indicated a downregulation of at
least five HDACs (Table 2). Our results were similar to pre-
vious reports, which indicated that statins and bisphospho-
nates act synergistically with HDAC inhibitors (65) and exert
a direct competitive inhibition of HDAC2 (6), leading to an
increased histone-H3 acetylation on the SP1 sites of the
promoter from CDKN1A (also known as P21).
Another study indicated that inhibiting HDAC5 originated
from a downregulation of the histone methylase EZH2 (66),
which was downregulated with both simvastatin and ibandr-
onate in our study.
Such modifications may stimulate expression of CDKN1A,
which is responsible for cell cycle arrest. A statin-induced cell
cycle arrest and an accumulation of CDKN1A were shown in
lymphoma cells (67). Thus, inhibition of isoprenoid synthesis
by statins could explain data indicating that these drugs
inhibit progression of epigenetically influenced diseases such
as cancer (68) and hematologic malignancies, as shown in a
survey of 578,000 adults (69).
Regulation of microRNAs
Small non-coding RNAs (microRNAs) play an important role
in the post-transcriptional regulation of a number of genesand their involvement in many pathological states, including
the metabolic syndrome and cancer (70). Statins were
shown to stimulate microRNA-33b (MIR-33b), which is
known to repress MYC, thus inducing a cell-cycle arrest in
G1 (21).
MicroRNA-33 is an intronic microRNA located within the
sterol regulatory element-binding protein (SREBP) genes,
which are one of the master regulators of cholesterol and
fatty acid metabolism. Furthermore, this microRNA regulates
the inflammatory cytokine production via cholesterol sensing
in macrophages (19).
Furthermore, statins are also known to affect expression
of microRNA-34a (Table 3), which regulates the NADþ-
dependent histone deacetylase SIRT1 (20) as well as
HDAC1 and HDAC7 (34). Simvastatin was also shown to
decrease microRNA-155 expression by interfering with the
mevalonate-geranylgeranyl-pyrophosphate-RhoA signaling
pathway (71).
Another target for microRNAs is the previously mentioned
TYMS, which was most significantly downregulated by sim-
vastatin or ibandronate in our study. The 30 untranslated re-
gion of TYMS has predicted binding sites for several
microRNA families, and altered expression of several
microRNAs has been reported in ovarian carcinoma (both
serous and unspecified type) when compared with normal
tissue. Predicted microRNA target sites at TYMS also
contain at least two polymorphisms (72). The MIR-34a is a
critical microRNA, which is responsible for DNA damage,
because it targets the TYMS gene (73) and also attacks
glycolysis (74).
The most significantly upregulated microRNA in the
simvastatin-treated MDA-MB 231 cells from our study was
microRNA-612 (Table 3), which is known to reduce stemness
and to relieve drug resistance to cisplatin and 5-fluorouracil,
possibly by targeting TYMS in cancer cells (35). MicroRNA-
612 was also significantly upregulated in simvastatin-
248 H. Karlic et al.treated PC-3 cells as well as in MG-63 and HMC-cells, which
had been treated with simvastatin (Table 4).
In addition, it appears possible that statin-associated
accumulation of Vitamin D might induce a larger number of
microRNAs (15).Epigenetic impact of targeted metabolic pathways
Results from our transcriptomics analyses (Figure 3)
demonstrated that statin-mediated downregulation of OCM
could inhibit DNA synthesis, repair, and methylation directly
(75) and indirectly via epigenetic activation of demethylated
genes as well as associated microRNAs (70).
Evidence exists that other epigenetically active com-
pounds, such as epigallocatechin-3-gallate (EGCG) that
shares with statins the potential to downregulate mevalonate
metabolism (76) as well as demethylating activity (77), also
act on folate metabolism (78,79).
A tight linkage of the DHFR and HMGCR genes exists on
chromosome 5q13.3-q14, and both genes are co-amplified in
cell lines (such as K562), which are resistant to the DHFR
inhibitor methotrexate (80). However, concerning gene
regulation, mRNA of HMGCR was not significantly regulated
with simvastatin or ibandronate, but a pronounced down-
regulation was observed for the DHFR and TYMS genes
(Table 4). In four of five investigated cell lines (MDA-MB-231,
MG-63, U2-OS, and HMC 1.1), both DHFR and TYMS were
downregulated, thus emphasizing the close metabolic as-
sociation of these two genes and their immediate impact on
the two principal epigenetic regulators, DNMT1 and HDAC2
(Tables 1 and 2).
Methylene THF is also a cofactor of TYMS, which con-
verts dUMP to dTMP by adding a methyl group. If cellular
folate levels are low, uracil misincorporation occurs, leading
to DNA strand breaks. Thus, the TYMS enzyme has been of
interest as a target for cancer chemotherapeutic agents. It is
considered to be the primary site of action for 5-fluorouracil,
5-fluoro-2-prime-deoxyuridine, and some folate analogs. On
the protein level, we detected a 24% downregulation of
TYMS with simvastatin (but no regulation of TYMS with
ibandronate, despite a significant downregulation of mRNA)
in U2-OS cells. This could confirm previous studies, which
indicate a possible stimulatory effect on cancer cells resulting
from folic acid fortification (81,82), which increases TYMS
activity (83e86). However, statin-mediated downregulation
of DNA repair may also result from a direct inhibition of
oncogenic RAS (87).
HMGCR reduces HMG-CoA to mevalonic acid. Cancer-
associated metabolic changes may shift the NA(P)Dþ/
NAD(P)H ratio toward NADPH, which is similar to alcohol
metabolism (88). Histone deacetylase activity is also
NADPþ-dependent; therefore, this could explain the similarity
of targeted pathways, such as cholesterol synthesis, which is
downregulated both by HDAC inhibitors (10) and simvastatin.
Possibly, the downregulation of TYMS by the HDAC inhibitor
vorinostat (89) could refer to downregulation of the same
pathway. The concordant downregulation of the DNMT1 and
HDAC2 genes could indicate some similarities in the action
from inhibitors of DNMT1 and HDACs.
The downregulation of the OCM metabolite HCys and an
associated epigenetically mediated stimulation of LOX(Table 5) could explain the beneficial effects of statins (90) and
bisphosphonates in osteoporosis (91). Furthermore, it has
been demonstrated that the propeptide of LOX (ppLOX),
which is the liberated form of the LOX precursor by cleavage
with protease bone morphogenetic protein 1 (BMP1), inhibits
cancer-associated DNA repair (92). Downregulation of TYMS
by both ibandronate and simvastatin in some of the tested cell
lines from our own study could explain a previous study that
demonstrated the effect of mevalonate pathway inhibitors on
DNA damage response in human sarcoma cells (93).
Targeting of the key epigenetic enzymes and key en-
zymes from OCM was also observed by treatment of the
FASN responsive cell line A2780 with the FASN inhibitor C75
or in the VD-responsive cell lines HL-60 and HMC-1.1 with
VD, which is well documented for its epigenetic impact (14).
However, the attenuation of downstream regulators of
FASN, as expected from treatment with C75 in the respon-
sive A2780 ovarian cancer cell line, was just partially
observed in simvastatin-treated cell lines (Figure 4). Recent
data indicating a specific protective role of statins (94)
against ovarian cancer underscore the possible impact of
metabolic therapies in this disease. The use of A2780 cells
as a model for the anticancer effect of simvastatin has been
documented (95).
Downstream signaling of FASN affects the RAS-PIK3 ki-
nase-AKT-mTOR pathways (54) and the associated role of
this pathway for HDAC inhibition (96), with the latter also
affected by treatment with statins and bisphosphonates
(3,97). Another study explained the association of the RAS-
PI3K-mTOR pathway to HDAC inhibition (5).
This emphasizes both the complex network of metabolic
pathways, which influence epigenetic reactions, and the
multiple activities from inhibitors of the mevalonic acid
pathway.Conclusion and clinical perspectives
Our research provides some models for epigenetic mecha-
nisms, which could explain many clinical studies that evalu-
ated the association between statin use and a lowered
cancer occurrence. Although populations encompassing
more than 1 million men have been screened, there is also
some controversy regarding the effectiveness of statins in
preventing prostate cancer (98,99). However, a direct effect
of statins on cultured cancer cells, including G1 cell cycle
arrest, autophagy, and proteolytic degradation of steroid re-
ceptors, is well documented (100,101). Breast cancer cells
treated in culture and in vivo as xenografts with lovastatin
had reduced proliferative ability, which further decreased in
the presence of BRCA1 overexpression via regulation of the
cell-cycle regulatory proteins cyclin D1-CDK4-p21WAF1/
CIP1 (102).
Critical evaluations (103) also discuss studies postulating
that statins could be a cancer-promoting class of drug, and,
indeed, the observed changes in downregulation of enzymes
that are associated with DNA repair or nucleotide synthesis,
for example, could be pro-cancerogenic when they occur in
normal cells.
However, the majority of studies indicates an inverse
correlation between statin use and cancer risk in the sense of
reduced cancer-related mortality among statin users (68).
Mevalonate pathway, epigenetics, and cancer 249More important, further clinical trials are under way, with the
primary end point of assessing the clinical utility of statins as
prevention measures for cancer (103).
Targeting of the mevalonic acid pathway represents an
example for a metabolic focus of targeting (potential) malig-
nancies and their (micro)environments. This is a prerequisite
for treatment assays as well as for future approaches for
personalized therapies.
Currently, bisphosphonate-based drugs are used to treat
bone diseases, including osteoporosis, tumor-induced hy-
percalcemia, and osteolytic cancer metastases (104). In
addition to skeletal benefits, clinical studies have shown that
bisphosphonates can suppress the proliferation of cancer
cells, including prostate (105), breast (106), and colorectal
cancers (107), as well as glioblastoma (108) and multiple
myeloma (MM) (109). Further investigations have also pro-
vided evidence that some bisphosphonates improve the
survival of patients with MM via mechanisms that may be
both related as well as unrelated to the skeletal benefits
(110,111). Similar results have been reported for patients
with premenopausal breast cancer (112), although these
findings seem to be more controversial (113).
In addition, the incidence of various types of inducible
breast cancers in rats and mice could be reduced by feeding
with statins, a process prevented by adding mevalonate, but
not by adding farnesyl pyrophosphate. In rodent models of
breast cancer, rats fed simvastatin had a lower incidence of
induced mammary tumors (114). Regarding the mechanism
of action, a significant mammary antitumor effect in mice via
decreased p-MEK1 and/or MEK2 protein levels was detec-
ted, which act in the RAS/RAF/MEK/ERK cascade that
drives cell proliferation (115), in addition to a proapoptotic
shift in the Bcl-2/Bax protein ratio (116).
Animal models have indicated the antiproliferative effects
of statins on lung, liver, colorectal (with evidence of epige-
netic reprogramming), melanoma, medulloblastoma,
ovarian, and prostate tumors (21,29,117e122).
Although the role of epigenetic markers in this scenario
remains to be confirmed in larger data sets, it appears clear
that the far-reaching epigenetic consequences from in-
hibitors of the mevalonic acid pathway are worth observing
and investigating in detail.
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